CTMX vs STT · rev $11.7M vs P/E 17, rev $7.84B
CytomX Therapeutics Inc (CTMX) versus State Street Corp (STT) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
State Street Corp (STT) is a asset management company listed on US.
Latest reported CTMX revenue for 2026-06-30 was $11.7M. Net income was -$38.9M. Revenue was up 13.8% from 2026-03-31 to 2026-06-30. CTMX currently screens at market cap $653.1M.
Latest reported STT revenue for 2026-06-30 was $7.84B. Net income was $1.85B. STT currently screens at market cap $45.02B and trailing P/E 16.5.
CTMX currently screens at market cap $653.1M. STT currently screens at market cap $45.02B and trailing P/E 16.5.
Not investment advice. Open the CTMX and STT stock pages for the full models.
Not investment advice.